RecruitingNCT06686485

cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia


Sponsor

Boston Scientific Corporation

Enrollment

433 participants

Start Date

Mar 18, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Subjects enrolled in the OPTION-A study will be clinically indicated for atrial fibrillation (AF) ablation procedure with the FARAPULSE™ PFA system and treatment with WATCHMAN LAAC Device, per physician's medical judgement and according to hospitals' standard of care during the same procedure.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Clinically indicated for treatment with both the FARAPULSE™ PFA system and with WATCHMAN for LAAC, per physician medical judgement and as per hospitals' standard of care.
  • Subjects who are willing and able to provide informed consent.
  • Subjects who are willing and able to participate in all testing associated with this clinical study at an approved clinical investigational center.
  • Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.

Exclusion Criteria17

  • Subjects who underwent prior AF ablation procedure.
  • Subjects with atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes.
  • Already surgically closed or otherwise excluded LAA.
  • The LAA anatomy does not accommodate a Closure Device.
  • Known or suspected atrial myxoma.
  • Presence of intracardiac thrombus.
  • Subjects with a current interatrial baffle or patch, history of atrial septal repair or has an ASD/PFO device.
  • Subjects with a presence of a mechanical valve prosthesis in any position.
  • Subjects with a myocardial infarction within 30 days prior to enrollment.
  • Subjects had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 90 days prior to enrollment.
  • Any planned electrical cardioversion within 30 days following LAAC device implant.
  • Subjects with a known inability to obtain vascular access.
  • Subjects with any contraindication to percutaneous catheterization procedure (e.g., patient size does not accommodate required catheters, ventriculotomy or atriotomy), active conditions (e.g. infection, bleeding disorder, unstable angina) or congenital abnormalities (severe rotational anomalies of the heart or great vessels) are present\*.
  • Subjects with any contraindications to short term use of anticoagulation therapy, or aspirin for conditions different from atrial fibrillation.
  • Subjects who are pregnant or planning to be pregnant.
  • Subjects with a life expectancy of ≤ 1 year per investigator's opinion.
  • Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be reviewed by the sponsor to determine eligibility.

Interventions

DEVICEFARAPULSE™ PFA system and WATCHMAN LAAC Delivery Systems

The FARAPULSE™ PFA System consists of the FARAWAVE™ Pulsed Field Ablation Catheter, the FARASTAR™ Pulsed Field Ablation Generator, and the FARADRIVE™ Steerable Sheath. The WATCHMAN LAA Closure Technology consists of the WATCHMAN Access System (which consists of the Access Sheath and Dilator and the WATCHMAN Delivery System (which consists of the delivery catheter and the pre-loaded closure device). The WATCHMAN Access System and WATCHMAN Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium.


Locations(29)

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Beijing Anzhen Hospital of the Capital University of Medical Sciences

Beijing, China

Xuanwu Hospital Capital Medical University

Beijing, China

Huaxi Hospital of Sichuan University

Chengdu, China

Guangdong Nanfang Hospital

Guangzhou, China

The Affiliated Hospital of Guizhou Medical University

Guiyang, China

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine

Hangzhou, China

QiLu Hospital of ShanDong University

Jinan, China

Shanxi Cardiovascular Hospital

Taiyuan, China

Zigong First People's Hospital

Zigong, China

Prince of Wales Hospital

Hong Kong, Hong Kong

Princess Margaret Hospital

Hong Kong, Hong Kong

Queen Mary Hospital

Hong Kong, Hong Kong

Queen Elizabeth Hospital

Kowloon, Hong Kong

Shonan Kamakura General Hospital

Kamakura-shi, Kanagawa, Japan

Sendai Kousei Hospital

Sendai, Miyagi, Japan

Kurashiki Central Hospital

Kurashiki-shi, Okayama Kurashiki-shi, Japan

Saitama Red Cross Hospital

Saitama, Saitama, Japan

Sakakibara Heart Institute, Sakakibara Heart Foundation

Fuchu-shi, Tokyo, Japan

Kokura Memorial Hospital

Fukuoka-ken, Japan

Yokosuka Kyosai Hospital

Kanagawa, Japan

Toho University Ohashi Medical Center

Meguro-ku, Japan

Osaka Keisatsu Hospital

Osaka, Japan

Institute Jantung Negara

Kuala Lumpur, Malaysia

Pusat Jantung Sarawak

Kuching, Malaysia

Asian Heart and Vascular Centre

Singapore, Singapore

Taichung Veterans General Hospital

Taichung, Taiwan

National Taiwan University Hospital

Taipei, Taiwan

Taipei Veterans General Hospital

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06686485


Related Trials